Ibrutinib Inhibits BTK Signaling in Tumor-Infiltrated B Cells and Amplifies Antitumor Immunity by PD-1 Checkpoint Blockade for Metastatic Prostate Cancer

SIMPLE SUMMARY: Metastatic prostate cancer has a poor clinical prognosis and is incurable. In recent decades, immune checkpoint blockade has revolutionized anticancer therapies and represents a potential way to control metastatic prostate cancer. Unfortunately, due to low immunoreactivity, patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Gengguo, He, Jiannan, Huang, Qunxiong, Li, Tengcheng, Huang, Zhansen, Gao, Shuntian, Xu, Jinbin, Wang, Tiantian, Di, Jinming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136622/
https://www.ncbi.nlm.nih.gov/pubmed/37190284
http://dx.doi.org/10.3390/cancers15082356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136622/
https://www.ncbi.nlm.nih.gov/pubmed/37190284
http://dx.doi.org/10.3390/cancers15082356

Ejemplares similares